Management of Methamphetamine-Induced Heart Failure with Reduced Ejection Fraction

Core Pharmacological Approach

The American College of Cardiology recommends treating methamphetamine-associated cardiomyopathy with quadruple guideline-directed medical therapy, including ARNI, evidence-based beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor, while pursuing methamphetamine abstinence as the foundation of therapy 1, 2
The preferred treatment includes ARNI, which provides at least 20% mortality reduction versus 5-16% for ACEi/ARBs, evidence-based beta-blockers, which provide at least 20% mortality reduction, mineralocorticoid receptor antagonists, which provide at least 20% mortality reduction, and SGLT2 inhibitors, regardless of diabetes status 1, 2
Combined quadruple therapy reduces mortality risk by approximately 73% over 2 years compared to no treatment, potentially extending life expectancy by 6 years compared to traditional dual therapy alone 1

The European Society of Cardiology recommends using a forced-titration approach with uptitration every 1-2 weeks until target doses are achieved, as used in landmark trials 3, 1
Asymptomatic low blood pressure should not prevent uptitration, and modest creatinine increases (up to 30% above baseline) are acceptable and should not prompt discontinuation 2, 1

Early follow-up within 7-14 days after medication adjustments is recommended, with monitoring for volume status changes, blood pressure, renal function, electrolytes, and worsening heart failure symptoms 1
Continue HFrEF medications even if ejection fraction improves, as discontinuation may lead to clinical deterioration 1

Loop diuretics should be added only if fluid overload is present, and consider cardiac resynchronization therapy if QRS duration is prolonged despite optimal medical therapy 1, 2